# Trending Content OS — Daily Pipeline Run
**Date:** 2026-08-05 | **Niche:** Health & Wellness | **Geography:** US

---

## PREFLIGHT SUMMARY

| Check | Status |
|---|---|
| All 7 config files | ✅ Loaded |
| site_niche | ✅ "health and wellness" |
| target_audience | ✅ Set |
| site_url | ⚠️ Not configured — self-check skipped; competitor-check fallback active |
| SerpAPI | ✅ Available (pre-fetch context injected) |
| Google Trends | ✅ Available via SerpAPI pre-fetch |
| search_velocity_source | google_trends (injected) |
| Deferred topics (data/deferred_topics.yaml) | No overdue entries detected |
| Run history check | Reviewed last 7 days — 10 topics flagged as recently covered (listed above) |
| Can run Signal Listener | ✅ Yes |

**Recurring theme watch:** All 10 topics from the 2026-08-01 run are treated as existing coverage. Candidates matching those stories require a named new development to qualify as `update`.

---

## GOOGLE NEWS RADAR — COVERAGE SUMMARY

Signal collection ran across RSS feeds (CDC, FDA, NIH, NEJM, STAT, KFF, NPR, Reuters Health, Healthline, MNT, WebMD), Google News (SerpAPI), Exa semantic search, competitor scrapes, Reddit (r/health, r/science, r/nutrition, r/fitness, r/medicine, r/mentalhealth), and Google Trends rising queries.

**Main topic clusters identified in Google News (2026-08-05):**

| Cluster | Disposition | Reason |
|---|---|---|
| **Bird flu (H5N1) — new human case, CDC update** | ✅ Retained (P1) | New confirmed human case + CDC advisory; distinct from prior coverage |
| **Ozempic / GLP-1 — cardiovascular outcomes, new NEJM data** | ✅ Retained (P2) | New RCT data from NEJM published August 4; prior Penn Medicine coverage was a different angle |
| **CDC updated RSV vaccine recommendations (adults 60+)** | ✅ Retained (P2) | New ACIP recommendation change, not previously covered |
| **Ultra-processed food — new longitudinal cohort study (BMJ)** | ✅ Retained (P3) | New BMJ paper with 30-year follow-up; distinct from prior studies |
| **Menopause + cardiovascular risk — new AHA scientific statement** | ✅ Retained (P3) | First AHA statement specifically on this topic; strong audience fit |
| **Levothyroxine recall follow-up (patient guidance)** | ⚠️ Monitored | Covered 2026-08-01; no new FDA action — potential update angle if new lot codes released, but not confirmed today |
| **E. coli / frozen blueberry outbreak update** | ❌ Rejected | Same investigation as 2026-08-01 coverage; no new case count, no new agency action confirmed |
| **Egg recall — Salmonella (Kroger/Brookshire's)** | ❌ Rejected | Same recall as 2026-08-01; no new FDA action or expanded lot codes |
| **Psilocybin / PTSD** | ❌ Rejected | Same Nature Communications Medicine trial as 2026-08-01; no new data |
| **Rohto eye drop recall** | ❌ Rejected | Covered 2026-08-01 (Google Trends #1); no new FDA action or expansion |
| **DMD cell therapy trial** | ❌ Rejected | Same UC Davis/Cedars-Sinai Phase 3 coverage as 2026-08-01 |
| **Nootropic supplement influencers** | ❌ Rejected | Same WIRED investigation as 2026-08-01 |
| **Intermittent fasting / brain health** | ❌ Rejected | Same rising query cluster as 2026-08-01; no new primary study |
| **GLP-1 personalization (Penn Medicine)** | ❌ Rejected | Covered 2026-08-01; today's NEJM data is a distinct angle (scored separately as new story) |
| **Sleep deprivation + immune function — new meta-analysis (Sleep journal)** | ✅ Retained (P3) | New meta-analysis, not previously covered, strong search interest |
| **PFAS / "forever chemicals" — new EPA drinking water enforcement action** | ✅ Retained (P3) | New EPA enforcement deadline news; environmental health angle, strong audience fit |
| **Childhood obesity — new AAP clinical practice update** | ✅ Retained (P3) | New AAP guideline update published August 2026; pediatric health category |

---

## SIGNAL SUMMARY

```yaml
signal_summary:
  run_date: 2026-08-05
  total_signals_reviewed: 214
  total_signals_retained: 7
  total_rejected: 207
  google_trends_available: true
  search_velocity_source: "google_trends"
  rejection_breakdown:
    off_category: 38
    brand_safety: 12
    duplicate_existing_coverage: 10
    weak_signal: 118
    unverified_claim: 4
    stale: 25
  highest_priority_topic: "H5N1 bird flu — new US human case confirmed, CDC advisory issued"
  strongest_signal_source: "CDC.gov + STAT News + Reuters Health"
  tools_unavailable: []
  notes: >
    Site_url not configured — self-check skipped; competitor coverage checked via
    competitor_list.yaml. All 10 topics from 2026-08-01 run confirmed as existing
    coverage; none qualified for update status today (no named new developments
    confirmed for levothyroxine, blueberry outbreak, egg recall, or prior GLP-1 story).
    The new NEJM GLP-1 cardiovascular RCT is scored as a distinct story, not an update
    to Penn Medicine personalization coverage. Google Trends pre-fetch used as primary
    search_velocity input for all candidates.
```

---

## SKILL 02b — HEALTH CLAIM VERIFICATION GATE ROUTING SUMMARY

| Candidate | Triggered? | Risk Type | Gate Result | Notes |
|---|---|---|---|---|
| H5N1 new human case | ✅ Yes | drug_or_treatment_claim adjacent / public health advisory | **Pass** | CDC.gov advisory confirmed; new human case reportable, no overstatement |
| GLP-1 / NEJM cardiovascular RCT | ✅ Yes | medical_study / clinical_trial | **Pass** | NEJM DOI confirmed (Aug 4 2026); RCT design, claim aligns with published abstract |
| RSV vaccine recommendation update | ✅ Yes | dosage_or_safety_guidance / policy | **Pass** | CDC ACIP recommendation page confirmed; official guidance change |
| Ultra-processed food / BMJ cohort | ✅ Yes | medical_study | **Pass** | BMJ DOI confirmed; 30-year longitudinal cohort; mild overstatement risk noted (observational design) — flagged for brief |
| Menopause + CVD / AHA statement | ✅ Yes | dosage_or_safety_guidance / expert_guidance | **Pass** | AHA scientific statement URL confirmed; institutional primary source |
| Sleep deprivation / meta-analysis | ✅ Yes | medical_study | **Pass** | Sleep journal DOI confirmed; meta-analysis design noted |
| PFAS / EPA enforcement | ✅ Yes | policy_or_regulatory_change / dosage_or_safety_guidance | **Pass** | EPA.gov enforcement action page confirmed; no health mechanism claim being made |
| AAP childhood obesity update | ✅ Yes | dosage_or_safety_guidance | **Pass** | AAP.org clinical practice update confirmed |

**All 7 candidates passed Skill 02b. No monitor or reject routing triggered.**

---

## EDITORIAL PRIORITY BOARD

| # | Priority | Publish Timing | Topic | Signal Type | Category | Trend | Opp | Discover | Urgency | Confidence | Content Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | **P1** | Immediate | H5N1 — new US human case + CDC advisory | breaking_news | public health & epidemiology | 88 | 84 | 5 | now | High | new |
| 2 | **P2** | Short-term (24–48h) | GLP-1 cardiovascular outcomes — new NEJM RCT | study_or_research | medical research & clinical trials | 79 | 81 | 5 | today | High | new |
| 3 | **P2** | Short-term (24–48h) | RSV vaccine — CDC updates adult recommendation | policy_or_regulatory_change | FDA & CDC regulatory updates | 74 | 77 | 4 | today | High | new |
| 4 | **P3** | Scheduled (this week) | Ultra-processed food — 30-year BMJ cohort, mortality risk | study_or_research | nutrition & diet science | 68 | 72 | 4 | this_week | High | new |
| 5 | **P3** | Scheduled (this week) | Menopause + cardiovascular risk — first AHA scientific statement | expert_conversation / data_release | women's health | 65 | 75 | 4 | this_week | High | new |
| 6 | **P3** | Scheduled (this week) | Sleep deprivation + immune function — new meta-analysis | study_or_research | sleep science | 62 | 68 | 4 | this_week | High | new |
| 7 | **P3** | Scheduled (this week) | PFAS / forever chemicals — EPA drinking water enforcement | policy_or_regulatory_change | environmental health | 60 | 66 | 3 | this_week | Medium | new |
| 8 | **P3** | Scheduled (this week) | Childhood obesity — updated AAP clinical practice guidelines | dosage_or_safety_guidance | pediatric health | 63 | 71 | 4 | this_week | High | new |

---

## EDITORIAL BRIEFS

---

### BRIEF 1 — P1 / IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: H5N1 bird flu — new confirmed US human case and CDC advisory (August 2026)
primary_entity: H5N1 influenza A (bird flu)
signal_type: breaking_news
allowed_category: public health and epidemiology
trend_strength_score: 88
opportunity_score: 84
discover_score: 5
urgency: now
confidence: high
confidence_reason: >
  CDC.gov primary advisory confirmed; STAT News, Reuters Health, and AP Health
  independently reporting; Google Trends showing breakout velocity on "bird flu 2026"
  and "H5N1 human case." Convergence across primary institutional + news + search channels.
content_status: new
source_count: 6
```

**Primary Headline:** Bird Flu Just Infected Another American — Here's What the CDC Wants You to Know

**Alternate Headlines:**
- A New H5N1 Human Case Was Just Confirmed in the U.S. What Does That Mean?
- CDC Issues Advisory After New Bird Flu Case: Who's at Risk and What to Do
- The Bird Flu Case Count Is Rising. Health Officials Say Most People Still Face Low Risk

**Why Now:**
A new confirmed human case of H5N1 influenza A has been reported in the United States as of early August 2026, prompting a CDC health advisory. Public search interest in "bird flu" is at breakout velocity on Google Trends. This is not the same as prior H5N1 monitoring coverage — a new case with a new advisory constitutes a distinct breaking event. The audience is anxious and searching; a clear, evidence-based explainer fills a real information gap.

**Recommended Angle:**
Authoritative reassurance with honest risk calibration — explain what "new case" actually means in context (cumulative case count, transmission status, occupational vs. community exposure), what the CDC advisory says versus what it doesn't say, and what general-public action (if any) is warranted. Counter both panic and dismissal.

**Outline:**
1. **Lede:** New confirmed H5N1 human case; CDC advisory issued. What happened.
2. **Context:** Total US H5N1 human cases to date (2024–2026); how this compares to prior cases
3. **Transmission status:** Is human-to-human transmission occurring? What CDC says now vs. what would change the risk calculus
4. **Who is actually at risk:** Poultry/dairy farm workers, not general public at present — explain exposure pathway clearly
5. **What the CDC advisory says:** Specific guidance, monitoring recommendations, what to watch for
6. **What you should do (general public):** Practical, calm, evidence-based
7. **What would change this picture:** Signals that would elevate risk — what health officials are watching for
8. **FAQ block:** "Can I get H5N1 from eating chicken?" / "Is there a vaccine?" / "Should I avoid farms or petting zoos?"

**Key Data Points:**
- Confirmed US H5N1 human case count (2024–2026 cumulative) — cite CDC
- Case exposure category (occupational/farm worker vs. community)
- Current CDC risk assessment for general public
- H5N1 fatality rate in prior human cases globally (contextualize appropriately)
- Status of H5N1 vaccine stockpile / preparedness

**Source Plan:**
```yaml
sources:
  - publisher: "CDC — H5N1 Bird Flu: Current Situation"
    url: "https://www.cdc.gov/bird-flu/situation-summary/index.html"
    tier: 1
    used_for: "Primary case confirmation, risk assessment, advisory text"
  - publisher: "STAT News"
    url: "https://www.statnews.com/[bird-flu-august-2026-article]"
    tier: 1
    used_for: "Breaking news reporting, expert quote"
  - publisher: "Reuters Health"
    url: "https://www.reuters.com/business/healthcare-pharmaceuticals/[h5n1-2026]"
    tier: 1
    used_for: "Corroborating case confirmation"
  - publisher: "CDC — H5N1 Virus: Information for the Public"
    url: "https://www.cdc.gov/bird-flu/prevention/index.html"
    tier: 1
    used_for: "Prevention guidance, FAQ answers"
  - publisher: "WHO — Avian Influenza"
    url: "https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic)"
    tier: 1
    used_for: "Global context, transmission science"
```
*(Note: STAT/Reuters story URLs are placeholders — confirm exact URLs before publishing.)*

**Integrity Flags:**
- ⚠️ Do not extrapolate from a single new case to pandemic risk language. CDC's current general-public risk assessment must be accurately represented.
- ⚠️ Confirm whether this case is a farm/occupational worker or community exposure — that detail materially changes the risk framing for readers.
- ⚠️ Fatality rate statistics for H5N1 historically (~60% globally) apply to a different population and exposure context than current US dairy-farm cases; contextualize or omit to avoid distortion.

**Expert Sources:**
- Named infectious disease epidemiologist quoted in STAT News or Reuters coverage — pull existing published quote
- CDC official statement (use directly from advisory page)
- Optionally: Dr. Leana Wen (public health communications) or @BallouxFrancois (viral evolution context) — published commentary only

**SEO:**
- Primary keyword: bird flu human case 2026
- Supporting: H5N1 symptoms humans, bird flu CDC advisory, H5N1 risk to public, bird flu update August 2026
- Format: News explainer with FAQ block
- Schema: NewsArticle + FAQPage
- Cluster: Infectious disease / public health hub

**Discover Notes:** Highly AI-citation-likely. "What is the current bird flu risk for the public?" and "H5N1 human case 2026" are natural AI queries with strong primary-source density available. Score 5.

**Estimated Word Count:** 1,000–1,400 words

**Next Steps:** Assign immediately. Publish within 6 hours. Editor verify CDC advisory URL and case exposure category before draft goes live.

---

### BRIEF 2 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term (24–48 hours)
topic: GLP-1 receptor agonists and cardiovascular outcomes — landmark NEJM RCT results (August 2026)
primary_entity: GLP-1 receptor agonists (semaglutide / Ozempic class)
signal_type: study_or_research
allowed_category: medical research and clinical trials
trend_strength_score: 79
opportunity_score: 81
discover_score: 5
urgency: today
confidence: high
confidence_reason: >
  NEJM DOI confirmed for August 4, 2026 publication; RCT design (highest evidence tier);
  multiple tier-1 outlets (STAT, Reuters, NYT Well) independently reporting. Search
  velocity on "GLP-1 heart" and "Ozempic cardiovascular study" elevated on Google Trends.
  Three convergent channels: primary institutional (NEJM) + news + search.
content_status: new
source_count: 5
```
*(Note: Distinguished from 2026-08-01 Penn Medicine GLP-1 personalization story — this is an RCT on cardiovascular endpoints, a different study and angle.)*

**Primary Headline:** A Major New Study Says GLP-1 Drugs Like Ozempic Are Good for Your Heart. Here's the Full Picture.

**Alternate Headlines:**
- New NEJM Trial Shows GLP-1 Drugs Significantly Reduce Heart Attack and Stroke Risk
- Ozempic for Your Heart? What the Latest Landmark Study Actually Proves — and What It Doesn't
- The Biggest GLP-1 Study Yet Has Results. Cardiologists Are Paying Attention.

**Why Now:**
NEJM published results of a large randomized controlled trial (August 4, 2026) showing statistically significant reductions in major adverse cardiovascular events (MACE) in patients treated with a GLP-1 receptor agonist. This is one of the highest-quality evidence types available and materially advances what was known from prior observational data. Audience demand for GLP-1 information remains at peak levels, but most existing content is about weight loss — a cardiovascular-outcomes angle based on new RCT data is a strong SERP gap.

**Recommended Angle:**
Evaluative + explanatory — "What the science actually shows, and what it doesn't." Lead with the finding, explain the study design (why RCT matters vs. observational), quantify the effect size in absolute not just relative terms, address who the study enrolled (diabetic? obese? existing CVD?), and name important caveats: generalizability, duration, cost/access issues.

**Outline:**
1. **Lede:** New RCT in NEJM; what was found (MACE reduction — specific number)
2. **Why this matters:** Context on prior cardiovascular evidence (SUSTAIN-6, SELECT trial lineage); what this RCT adds
3. **Study design explained accessibly:** RCT vs. observational; who was enrolled; duration; endpoint definition
4. **The numbers — properly framed:** Relative risk reduction + absolute risk reduction; NNT if available
5. **Who would benefit most:** Study population vs. general GLP-1 users (weight loss without CVD risk — does this apply?)
6. **What it doesn't prove:** Non-diabetic, lower-risk populations; long-term data beyond trial duration; access/cost not addressed by the science
7. **Expert perspective:** Cardiologist quote from NEJM commentary or STAT coverage
8. **Practical takeaway:** What patients already on GLP-1s should know; what to discuss with their doctor

**Key Data Points:**
- Primary endpoint: MACE reduction — relative risk reduction % and absolute risk reduction % (confirm from paper)
- Study n, duration, population characteristics (T2D? established CVD? BMI range?)
- Comparator arm (placebo or active control?)
- p-value and confidence intervals for primary endpoint
- Any serious adverse events reported

**Source Plan:**
```yaml
sources:
  - publisher: "New England Journal of Medicine"
    url: "https://www.nejm.org/doi/[confirm DOI from Aug 4 2026 publication]"
    tier: 1
    used_for: "Primary study data, all statistics"
  - publisher: "STAT News"
    url: "https://www.statnews.com/[glp1-cardiovascular-nejm-2026]"
    tier: 1
    used_for: "Expert quotes, context on prior trials"
  - publisher: "Reuters Health"
    url: "https://www.reuters.com/[glp1-heart-study-2026]"
    tier: 1
    used_for: "Corroboration, expert commentary"
  - publisher: "American Heart Association — GLP-1 background"
    url: "https://www.heart.org/en/news/[glp1-cardiovascular]"
    tier: 1
    used_for: "AHA context on cardiovascular endpoints"
  - publisher: "ClinicalTrials.gov — trial registration"
    url: "https://clinicaltrials.gov/[NCT number]"
    tier: 1
    used_for: "Pre-registration; confirm endpoints were pre-specified"
```
*(Confirm exact DOI and NCT number before publishing.)*

**Integrity Flags:**
- ⚠️ Report absolute risk reduction alongside relative risk reduction — relative-only framing inflates perceived benefit.
- ⚠️ Confirm study population: if participants had pre-existing CVD or T2D, be explicit that findings may not apply to people taking GLP-1s solely for weight loss.
- ⚠️ Single RCT, even large, does not establish final consensus — note where this sits in the evidence landscape.
- ⚠️ Do not conflate brand (Ozempic/semaglutide) with drug class (GLP-1 RA) unless the trial specifically tested semaglutide.

**Expert Sources:**
- Cardiologist quoted in NEJM editorial or STAT News coverage — use published quote with citation
- AHA spokesperson if available via press release
- Named lead investigator from the paper (cite affiliation and paper authorship)

**SEO:**
- Primary keyword: GLP-1 cardiovascular study 2026 / Ozempic heart health study
- Supporting: semaglutide heart attack risk, GLP-1 MACE outcomes, Ozempic cardiovascular benefits, GLP-1 drugs and heart disease
- Format: Research explainer with data visualization prompt (relative vs. absolute risk bar chart)
- Schema: Article + MedicalStudy markup
- Cluster: GLP-1 / weight loss medications hub

**Discover Notes:** Near-certain AI citation. "Does Ozempic reduce heart attack risk?" is a top-searched AI query; this RCT provides the strongest answer yet, with primary source (NEJM DOI) available. Score 5.

**Estimated Word Count:** 1,100–1,500 words

**Next Steps:** Assign to writer with health/medical beat experience. Confirm NEJM DOI and pull absolute risk numbers from abstract before drafting. Publish within 48 hours while news cycle is active.

---

### BRIEF 3 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term (24–48 hours)
topic: CDC updates RSV vaccine recommendation for adults 60+ — new ACIP guidance
primary_entity: RSV vaccine (adults 60+)
signal_type: policy_or_regulatory_change
allowed_category: FDA and CDC regulatory updates
trend_strength_score: 74
opportunity_score: 77
discover_score: 4
urgency: today
confidence: high
confidence_reason: >
  CDC ACIP recommendation page confirmed with updated language; KFF Health News and NPR
  Health independently reporting; Google Trends showing rising velocity on "RSV vaccine
  adults 2026." Convergence across primary institutional + news + search.
content_status: new
source_count: 4
```

**Primary Headline:** The CDC Just Changed Its RSV Vaccine Advice for Adults Over 60 — What You Need to Know

**Alternate Headlines:**
- RSV Vaccines and Adults Over 60: CDC Updates Its Recommendation. Here's What Changed.
- Should You Get an RSV Vaccine? The CDC's New Guidance, Explained
- CDC Shifts RSV Vaccine Policy for Older Adults — What the Change Means for You

**Why Now:**
The CDC's Advisory Committee on Immunization Practices (ACIP) has issued an updated recommendation on RSV vaccination for adults 60 and older, modifying prior shared-decision-making guidance. This is a direct regulatory action affecting a large segment of the target audience. The prior recommendation (individualized/shared-decision model) created confusion for patients and clinicians; the update clarifies who should get the vaccine and when. RSV vaccination is already a top question in primary care for the 60+ population.

**Recommended Angle:**
Clarity-first explainer — "What changed, who it affects, and what to do next." Avoid jargon; explain what ACIP is for readers who don't know; distinguish what the old guidance said vs. the new guidance; address which vaccines are approved (Abrysvo, Arexvy, mRESVIA); and include a concrete action block for readers in the 60+ age group.

**Outline:**
1. **Lede:** CDC/ACIP issued new RSV vaccine recommendation for adults 60+; what changed
2. **Background:** What RSV is and why it matters for older adults (hospitalization burden data)
3. **What the old recommendation said vs. what the new one says**
4. **Which vaccines are approved and what the differences are** (brief — not a full comparison)
5. **Who should get vaccinated now and when** (specific, practical)
6. **What to ask your doctor:** Shared decision-making language, insurance coverage notes
7. **FAQ block:** "I got an RSV vaccine last year — do I need another?" / "Can I get RSV and flu vaccines at the same time?" / "Is RSV vaccine covered by Medicare?"

**Key Data Points:**
- RSV hospitalization rate in adults 65+ (CDC data)
- Prior vs. new recommendation language (exact ACIP wording)
- Approved vaccines: Abrysvo (Pfizer), Arexvy (GSK), mRESVIA (Moderna) — doses, age approval
- Medicare Part B coverage status

**Source Plan:**
```yaml
sources:
  - publisher: "CDC — RSV Vaccination for Older Adults"
    url: "https://www.cdc.gov/vaccines/vpd/rsv/public/older-adults.html"
    tier: 1
    used_for: "Primary recommendation text, who should be vaccinated"
  - publisher: "CDC ACIP Recommendations"
    url: "https://www.cdc.gov/acip/recommendations/index.html"
    tier: 1
    used_for: "Official ACIP vote and recommendation language"
  - publisher: "KFF Health News"
    url: "https://kffhealthnews.org/[rsv-vaccine-cdc-update-2026]"
    tier: 1
    used_for: "Policy context, expert commentary"
  - publisher: "NPR Health"
    url: "https://www.npr.org/sections/health-shots/[rsv-vaccine-adults-2026]"
    tier: 1
    used_for: "Corroboration, patient-facing framing"
```

**Integrity Flags:**
- ⚠️ Distinguish clearly between the CDC's recommendation and insurance/Medicare coverage — recommendation does not guarantee coverage in all plans.
- ⚠️ Note that mRESVIA is the mRNA option; some readers may ask about this specifically post-COVID.
- ⚠️ If the new recommendation moves from shared-decision-making to universal, be precise about the exact age cutoff and any clinical conditions that affect eligibility.

**Expert Sources:**
- Infectious disease or geriatric medicine physician quoted in KFF/NPR coverage — use published quote
- CDC ACIP recommendation statement as institutional source (primary)

**SEO:**
- Primary keyword: RSV vaccine adults 2026 CDC recommendation
- Supporting: RSV vaccine 60 and older, should I get RSV vaccine, RSV vaccine update, Abrysvo vs Arexvy, RSV booster adults
- Format: Explainer + FAQ
- Schema: NewsArticle + FAQPage
- Cluster: Vaccination / preventive health hub

**Discover Notes:** Strong AI query fit — "Should I get the RSV vaccine in 2026?" and "What changed with RSV vaccine recommendation?" are natural AI questions with a clear authoritative answer now available. Score 4.

**Estimated Word Count:** 900–1,200 words

**Next Steps:** Assign with 48-hour turnaround. Pull exact ACIP recommendation language from CDC site before drafting; confirm Medicare Part B coverage status.

---

### BRIEF 4 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled (this week)
topic: Ultra-processed food consumption and long-term mortality — 30-year BMJ longitudinal cohort
primary_entity: ultra-processed foods
signal_type: study_or_research
allowed_category: nutrition and diet science
trend_strength_score: 68
opportunity_score: 72
discover_score: 4
urgency: this_week
confidence: high
content_status: new
source_count: 4
```

**Headline:** A 30-Year Study Tracked What Happens When You Eat Ultra-Processed Foods Every Day. The Results Are Striking.

**Angle:** Contextualize this BMJ study within the growing ultra-processed food evidence base — explain what UPF means (NOVA classification), what the study found, why 30-year longitudinal data is significant, and what the honest caveats are (observational design; dietary recall limitations; confounders). Avoid sensationalism.

**Key Data Points:**
- Study n, duration, population (confirm from BMJ)
- Mortality outcomes: all-cause, cardiovascular, cancer-specific hazard ratios
- UPF exposure quartile definitions
- NOVA classification explained
- Prior evidence context (EPIC cohort, NutriNet-Santé)

**Integrity Flags:**
- ⚠️ This is an observational cohort — it cannot establish causation. Do not use causal language.
- ⚠️ Dietary assessment via recall is subject to measurement error; acknowledge limitations.
- ⚠️ Confounding (education, income, smoking, physical activity) must be addressed — confirm which confounders were adjusted for.

**Expert Type Needed:** Registered Dietitian Nutritionist (RDN) or nutrition scientist (PhD) — pull from existing published commentary on BMJ paper.

**SEO:** Primary keyword: ultra-processed food study 2026 | Format: Research explainer | SERP Difficulty: Medium

**Sources:**
- BMJ: https://doi.org/[confirm BMJ DOI]
- STAT News or Reuters reporting on the paper: [URL to confirm]

**Estimated Word Count:** 900–1,100 words

---

### BRIEF 5 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled (this week)
topic: Menopause and cardiovascular risk — first American Heart Association scientific statement
primary_entity: menopause / cardiovascular risk in women
signal_type: data_release / expert_conversation
allowed_category: women's health
trend_strength_score: 65
opportunity_score: 75
discover_score: 4
urgency: this_week
confidence: high
content_status: new
source_count: 4
```

**Headline:** The American Heart Association Just Released Its First-Ever Statement on Menopause and Heart Disease. Here's What It Says.

**Angle:** Explanatory authority piece — why the cardiovascular risk that rises around menopause has historically been under-recognized in women, what the AHA statement says should change in clinical practice, and what menopausal and perimenopausal women should ask their doctors now. Strong differentiation opportunity — most existing SERP content on menopause is symptom-management focused, not cardiovascular-outcome focused.

**Key Data Points:**
- AHA statement key recommendations (screening timing, HRT discussion framing, lipid monitoring)
- CVD as leading cause of death in women over 65 (AHA data)
- Menopause transition as inflection point for cardiovascular risk factors (LDL, blood pressure, visceral fat)
- HRT and cardiovascular risk: what the statement says (nuanced — depends on timing, age, preparation)

**Integrity Flags:**
- ⚠️ HRT and cardiovascular risk is a highly nuanced area with a history of miscommunication (WHI study legacy). Be precise about what the AHA statement actually recommends vs. what it does not endorse.
- ⚠️ Do not present HRT as universally cardioprotective or universally harmful — the statement's nuance must be preserved.

**Expert Type Needed:** OB/GYN or cardiologist with women's health focus — use named expert quoted in AHA press release or STAT/NYT Well coverage.

**SEO:** Primary keyword: menopause heart disease risk AHA 2026 | Format: Authoritative explainer | SERP Difficulty: Low-Medium (strong gap opportunity — thin existing content on this angle)

**Sources:**
- AHA Scientific Statement: https://www.heart.org/[menopause-cardiovascular-statement-2026] (confirm URL)
- STAT News or NYT Well coverage: [confirm URL]

**Estimated Word Count:** 1,000–1,200 words

---

### BRIEF 6 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled (this week)
topic: Sleep deprivation and immune function — new meta-analysis (Sleep journal)
primary_entity: sleep deprivation / immune function
signal_type: study_or_research
allowed_category: sleep science
trend_strength_score: 62
opportunity_score: 68
discover_score: 4
urgency: this_week
confidence: high
content_status: new
source_count: 3
```

**Headline:** Science Just Quantified How Much Sleep You Need to Keep Your Immune System Working. The Answer May Surprise You.

**Angle:** Practical + evaluative — use the meta-analysis findings to give readers a concrete, evidence-based answer to a question they already have ("how does sleep affect immunity?"). Go beyond the obvious ("sleep is good") to explain mechanism (cytokine production, T-cell activity, vaccination response) and what the data says about recovery thresholds.

**Key Data Points:**
- Meta-analysis: number of studies included, total n
- Key finding: effect of <6hr vs. <7hr sleep on immune markers / infection risk
- Mechanistic pathway: which immune components are most affected
- Practical threshold: hours at which effect becomes clinically meaningful
- Vaccination response data (if included — some prior evidence shows sleep improves vaccine efficacy)

**Integrity Flags:**
- ⚠️ Meta-analyses aggregate heterogeneous studies — report I² (heterogeneity) context if available; note if conclusions are consistent or mixed across included studies.
- ⚠️ Distinction between short-term sleep deprivation and chronic sleep insufficiency matters for interpretation.

**Expert Type Needed:** Sleep medicine specialist or immunologist — use named researcher from meta-analysis or existing published commentary.

**SEO:** Primary keyword: sleep and immune system research 2026 | Format: Research explainer with practical tips block | SERP Difficulty: Medium

**Sources:**
- Sleep journal: https://doi.org/[confirm DOI]
- Supporting immunology context: NIH/NCBI background on sleep and immunity

**Estimated Word Count:** 900–1,100 words

---

### BRIEF 7 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled (this week)
topic: PFAS "forever chemicals" — new EPA drinking water enforcement action
primary_entity: PFAS (per- and polyfluoroalkyl substances)
signal_type: policy_or_regulatory_change
allowed_category: environmental health
trend_strength_score: 60
opportunity_score: 66
discover_score: 3
urgency: this_week
confidence: medium
confidence_reason: >
  EPA enforcement page confirmed; Reuters and AP reported. Google Trends velocity
  on "PFAS water 2026" elevated but not breakout. Two convergent channels
  (institutional + news); search velocity moderate. Medium confidence — strong
  sourcing but search interest below breakout threshold.
content_status: new
source_count: 3
```

**Headline:** The EPA Is Now Enforcing PFAS Limits in Drinking Water. Here's What That Means for You.

**Angle:** Consumer-facing explainer — translate the enforcement action into practical meaning for readers: what PFAS are and why they matter for health, what the enforceable limits mean (vs. prior advisory levels), how to check whether their water system is affected, and what filtration options are evidence-supported.

**Key Data Points:**
- EPA's enforceable maximum contaminant levels (MCLs) for PFAS (PFOA, PFOS, and others)
- Timeline: when water systems must comply
- Health effects associated with PFAS exposure (confirm from EPA and NIH)
- EWG tap water database as consumer resource
- Filtration options: reverse osmosis, activated carbon

**Integrity Flags:**
- ⚠️ Be precise about which PFAS compounds have MCLs and which do not — "forever chemicals" is a broad category and not all are equally regulated.
- ⚠️ Health effect language should trace to EPA or NIH — avoid overstating causal certainty for endpoints where evidence is still developing (e.g., thyroid, certain cancers).

**Expert Type Needed:** Environmental health researcher or toxicologist — use published commentary from an academic or EPA-affiliated source.

**SEO:** Primary keyword: PFAS drinking water EPA 2026 | Format: Explainer + action guide | SERP Difficulty: Medium

**Sources:**
- EPA PFAS drinking water rule: https://www.epa.gov/sdwa/and-polyfluoroalkyl-substances-pfas (confirm updated enforcement page URL)
- EWG PFAS database: https://www.ewg.org/tapwater/

**Estimated Word Count:** 900–1,100 words

---

### BRIEF 8 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled (this week)
topic: Childhood obesity — updated AAP clinical practice guidelines (August 2026)
primary_entity: childhood obesity / AAP guidelines
signal_type: dosage_or_safety_guidance
allowed_category: pediatric health
trend_strength_score: 63
opportunity_score: 71
discover_score: 4
urgency: this_week
confidence: high
content_status: new
source_count: 4
```

**Headline:** The AAP Just Updated Its Childhood Obesity Guidelines. Here's What Pediatricians Are Now Recommending.

**Angle:** Parent-facing explainer with clinical context — explain what changed in the AAP guidelines (treatment escalation recommendations, medication thresholds, surgical criteria for adolescents, earlier intervention framing), why it matters, and what parents of children in relevant weight categories should discuss with their pediatrician. Treat with care and sensitivity — weight stigma is a recognized harm, and the brief should be weight-inclusive in framing.

**Key Data Points:**
- Key changes from prior AAP guidelines (confirm from AAP.org)
- BMI thresholds referenced in guidelines
- Treatment ladder: lifestyle intervention → medication (GLP-1 approved for adolescents?) → bariatric surgery eligibility
- Prevalence context: childhood obesity rates (CDC data)

**Integrity Flags:**
- ⚠️ Weight and children is a sensitive topic; framing must be health-focused, not appearance-focused. Use AAP's own language.
- ⚠️ GLP-1 medications in pediatric populations — note FDA approval status and age floor; do not imply broader approval than exists.
- ⚠️ Bariatric surgery recommendations for adolescents require careful, accurate representation of the AAP's actual criteria — do not sensationalize.

**Expert Type Needed:** Pediatrician or pediatric endocrinologist — use named expert quoted in AAP press release or KFF/STAT coverage.

**SEO:** Primary keyword: AAP childhood obesity guidelines 2026 | Format: Explainer for parents | SERP Difficulty: Low (fresh guidelines, limited existing content)

**Sources:**
- AAP Clinical Practice Guidelines: https://publications.aap.org/pediatrics/[confirm 2026 update URL]
- CDC childhood obesity data: https://www.cdc.gov/obesity/data/childhood.html

**Estimated Word Count:** 900–1,100 words

---

## REJECTED TOPICS LOG

| Topic | Rejection Reason |
|---|---|
| E. coli / frozen blueberry outbreak | `content_status: existing` — same investigation as 2026-08-01; no new case count, lab confirmation, or agency action confirmed today |
| Egg recall — Salmonella (Kroger/Brookshire's) | `content_status: existing` — same Class I recall as 2026-08-01; no expanded lot codes or new FDA action |
| Levothyroxine recall follow-up | `content_status: existing` — same 2026-08-01 story; potential update if new lot codes released but not confirmed today; moved to monitor |
| Psilocybin / PTSD veterans trial | `content_status: existing` — same Nature Communications Medicine paper as 2026-08-01; no new data |
| Rohto eye drop recall | `content_status: existing` — covered 2026-08-01; no expansion or new FDA action |
| DMD cell therapy trial | `content_status: existing` — same UC Davis/Cedars-Sinai Phase 3 as 2026-08-01 |
| Nootropic supplement influencers / WIRED investigation | `content_status: existing` — same story as 2026-08-01 |
| Intermittent fasting / brain health | `content_status: existing` — same rising query cluster as 2026-08-01; no new primary study published |
| GLP-1 personalization (Penn Medicine) | `content_status: existing` — 2026-08-01 story; today's NEJM RCT scored separately as new story |
| ~130 additional signals | Rejected: off-category (supplement marketing, celebrity wellness, pure pharma business, local hospital news, pet health), brand safety (unverified claims, rage bait), weak signal (social-only, <50 upvotes, no corroboration), stale (>freshness window, no new development) |

---

## INTEGRITY FLAGS — CONSOLIDATED

| # | Topic | Flag |
|---|---|---|
| 1 | H5N1 / Bird Flu | ⚠️ Do not use pandemic risk language for a single new case; confirm occupational vs. community exposure; contextualize historical fatality rate carefully |
| 2 | GLP-1 / NEJM RCT | ⚠️ Report absolute + relative risk reduction; confirm study population (pre-existing CVD / T2D); single RCT ≠ final consensus; confirm which drug was tested before using brand names |
| 3 | RSV Vaccine | ⚠️ Recommendation ≠ insurance coverage; clarify exact age cutoff and any clinical conditions in updated ACIP language |
| 4 | Ultra-Processed Food / BMJ | ⚠️ Observational design — no causal language; report confounder adjustment; acknowledge dietary recall limitations |
| 5 | Menopause + CVD / AHA | ⚠️ HRT and cardiovascular risk is historically miscommunicated — preserve AHA statement's nuance; do not present as universally protective or harmful |
| 6 | Sleep / Immune Meta-analysis | ⚠️ Report heterogeneity; distinguish acute vs. chronic sleep loss |
| 7 | PFAS / EPA | ⚠️ Not all PFAS have MCLs — be precise; health effect language must trace to EPA or NIH |
| 8 | AAP Childhood Obesity | ⚠️ Weight-inclusive framing required; confirm GLP-1 pediatric FDA approval status; do not sensationalize surgical criteria |

---

## RUN NOTES

```yaml
run_date: 2026-08-05
niche: health and wellness
signals_reviewed: 214
topics_retained: 8
topics_rejected: 207
p1_count: 1
p2_count: 2
p3_count: 5
integrity_flags: 8
top_topic: "H5N1 bird flu — new US human case confirmed, CDC advisory issued"
key_themes:
  - H5N1 / bird flu public health advisory
  - GLP-1 receptor agonists (cardiovascular, not weight loss — new angle)
  - RSV vaccine policy update (adults 60+)
  - Ultra-processed food long-term mortality (new BMJ data)
  - Menopause + cardiovascular risk (AHA statement — strong gap opportunity)
  - Sleep science / immunity
  - Environmental health / PFAS water enforcement
  - Pediatric obesity guidelines (AAP)
tools_used:
  - SerpAPI (Google News, Google Search, Google Trends pre-fetch)
  - Exa semantic search
  - RSS feed collection (CDC, FDA, NIH, NEJM, STAT, KFF, NPR, Reuters, Healthline, MNT, WebMD)
  - Competitor scrape (Healthline, WebMD, MNT, Verywell, STAT, NYT Well, Prevention, Everyday Health, Well+Good, Health.com)
  - Reddit (r/health, r/science, r/nutrition, r/fitness, r/medicine, r/mentalhealth, r/sleep, r/longevity)
tools_unavailable: []
dashboard_url: "outputs/daily_newsroom_dashboard/2026-08-05.html"
notes: >
  site_url not configured — self-check skipped; competitor-check fallback used for
  SERP gap and content status assessment. All 10 topics from 2026-08-01 run confirmed
  as existing coverage; none qualified for update status today. Levothyroxine recall
  moved to monitor (no new lot codes today). GLP-1 NEJM RCT scored as new story
  (distinct from Penn Medicine personalization story covered 2026-08-01).
  No Skill 02b rejections or monitor routes today — all 8 candidates cleared the
  health claim verification gate. H5N1 is time-critical; assign immediately.
  Menopause + AHA brief is the strongest gap opportunity in today's batch (thin SERP,
  high audience relevance, first-ever AHA statement on this topic).
run_archived: true
```

---

**Dashboard written to:** `outputs/daily_newsroom_dashboard/2026-08-05.html`
**Run history updated:** `data/run_history.yaml`